Current standards, donor safety, and blood supply

Slides:



Advertisements
Similar presentations
CBER Isolagen Therapy (IT) BLA FDA Clinical Review Agnes Lim, MD Yao-Yao Zhu, MD, PhD DCEPT/OCTGT/CBER, FDA October 9, 2009 Advisory Committee Meeting.
Advertisements

Peterson-Kaiser Health System Tracker How do health expenditures vary across the population?
Maintaining a Safe and Adequate Supply of Donated Blood During a Severe Emergency Alan E. Williams, Ph.D. Associate Director for Regulatory Affairs, OBRR,
Supplemental Testing of Donors for HIV and HCV September 18, 2003 BPAC Meeting Robin Biswas, M.D. Indira Hewlett, Ph.D. FDA/CBER/OBRR/DETTD.
Blood Donor Written Statement of Understanding
Draft Guidance for Industry: Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob.
Hemoglobin Determination. Hemoglobin — Found in the RBC. — Responsible for carrying oxygen to all cells in the body. — Also binds to carbon dioxide and.
CDC Recommendations for Lead Poisoning Prevention in Newly Arrived Refugee Children Medical Provider Module U.S. Department of Health and Human Services.
Public Workshop: Quarantine Release Errors in Blood Establishments September 13, 2011 QREs Past, Present and Future Sheryl A. Kochman Deputy Director Division.
Iron Status in Blood Donors Barbara J. Bryant, MD University of Texas Medical Branch Galveston, Texas and Department of Transfusion Medicine National Institutes.
Clinical and Surrogate Endpoints for Evaluating Efficacy of Alpha 1 - Proteinase Inhibitor (Human) Augmentation Therapy Topic II - Introduction Blood Products.
2010 Guidelines from the American Academy of Pediatrics.
1 Risks and Benefits of Home-Use HIV Test Kits Richard Forshee, Ph.D. U.S. Food and Drug Administration Center for Biologics Evaluation and Research Office.
Microhematocrit.
Special Topics in IND Regulation
How and why attitudes to the roles of men and women have changed
1 Babesia BPAC: FDA Perspective Sanjai Kumar, PhD Division of Emerging and Transfusion- Transmitted Diseases Office of Blood Research and Review CBER,
CBER Cooperative Manufacturing Arrangements (Contractors) Jennifer Jones Consumer Safety Officer CBER, OBRR, DBA September 15, 2009.
CBER 1 Current standards, donor safety and blood supply Orieji Illoh, MD Office of Blood Research and Review Center for Biologics Evaluation and Research.
Role of Clinicians in Promoting Voluntary Blood Donation Dr. Anju Verma.
Workshop Summary FDA Workshop on Testing for malarial Infections in Blood Donors Sanjai Kumar, Ph.D. Center for Biologics Evaluation and Research Food.
CBER Managed Review Process Sheryl A. Kochman Deputy Director, DBA, OBRR, CBER September 15, 2009.
The amount of additional iron needed for RBCs expansion depends on the numbers of fetuses. WHO recommends iron supplements 30–60 mg/day if the woman has.
Parvovirus B19 NAT for Whole Blood and Source Plasma Introduction and Background Mei-ying W Yu, PhD DH/OBRR/CBER/FDA 75 th Blood Products Advisory Committee.
Classification of HLA Devices FDA Introduction & Background Sheryl A. Kochman CBER/OBRR/DBA.
Introduction to Standard 2: Partnering with consumers Advice Centre Network Meeting Nicola Dunbar October 2012.
CBER Hemoglobin/Hematocrit Acceptance Standards and Interdonation Interval in Blood Donors Introduction Blood Products Advisory Committee July 27, 2010.
CBER Hemoglobin/Hematocrit Acceptance Standards and Interdonation Interval in Blood Donors Summary and Questions for the Committee Blood Products Advisory.
Proposed changes to hemoglobin and donation interval criteria for whole blood donors: Projected impact on current donor base Anne Eder, MD PhD Executive.
Experimental Design The Gold Standard?.
Deferral of MSM by Andrew I. Dayton, M.D., Ph. D. The HIV epidemic in the U.S.A. is generally recognized to have started just after Currently MSM.
Update: Lowering Measles Antibody Lot Release Specification in IGIV/IGSC Blood Products Advisory Committee May 1, 2008 Dorothy Scott, M.D. Division of.
FDA Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components.
Iron Deficiency Anemia
Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.
INTRODUCTION TO ANEMIA Definition. Age, Sex and other factors. Causes of Anemia. Clinical diagnosis. Classification of Anemia. Laboratory Tests in the.
CBER Red Blood Cell Immunization Programs Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.
ICH V2 An FDA Update Susan Lu Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.
Challenges in evaluating and changing donor criteria Dr. Mindy Goldman Transfusion Medicine Residents April 30, 2008.
Current Considerations on Plasma for Further Manufacturing Obtained from Whole Blood Donors Alan E. Williams, Ph.D. Associate Director for Regulatory Affairs,
Monthly Journal article review: Vimmi Kang PGY 2
CBER’s Blood Safety Team Blood Products Advisory Committee 01 May 2008 Jonathan C. Goldsmith, MD Office of Blood Research and Review.
Abbreviated Donor History Questionnaire: Background and Introduction Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee March 2005.
Blood Center Experience with Double Red Cell Collections by Apheresis: Adverse Events and Impact on Capacity Brian Custer, Hany Kamel, Marj Bravo Peter.
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Microhematocrit Determination. Microhematocrit Hematocrit — Test that provides a health care worker with an estimate of the patient’s red cell volume.
Hemoglobin Device Regulation Josephine Bautista, M.S., MT (ASCP) Senior Advisor for IVD Regulation DRB/DBA/OBRR/CBER Workshop: Hemoglobin standards and.
HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary for FDA’s BPAC July 2010 Jerry A. Holmberg, Ph.D. Senior Advisor for Blood.
FDA Perspective on the PASSPORT Study FDA Perspective on the PASSPORT Study Salim A. Haddad, M.D. Laboratory of Cellular Hematology Division of Hematology.
Topic 1: FDA Draft Guidance “Revised Preventive Measures to Reduce the Possible Risk of Transmission of CJD and vCJD by Blood and Blood Products” Dorothy.
Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection - Update - Alan E. Williams, Ph.D. Director,
Deferral of Blood and Plasma Donors for History of Transfusion in BSE Countries of Europe Alan E. Williams, Ph.D. Director, Division of Blood Applications.
Statistical Methods in the Evaluation of Red Blood Cell Products (In vivo study) Jessica Kim, Ph.D. Mathematical Statistician FDA/CBER/OBE/DB Blood Products.
HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary of November 2010 ACBSA for FDA’s BPAC December 2010 CDR Richard Henry, USPHS.
Application of the 1998 Pediatric Rule to Oncology Steven Hirschfeld, MD PhD CDR U.S. Public Health Service Medical Officer Division of Oncology Drug Products.
Proposed Workshop: Hemoglobin Standards and Maintenance of Iron Stores in Blood Donors Blood Product Advisory Committee April 29, 2011.
Allogeneic donor selection and blood collection by Mohammed Abu-basha 1.
Transfusion Related Acute Lung Injury (TRALI)
Confidential Unit Exclusion Donors may be given the opportunity to indicate confidentially whether their blood is or is not suitable for transfusion to.
FDA’s vCJD Risk Communication on US Plasma- Derived Factor VIII and UK Plasma-Derived Factor XI BPAC April 27, 2007 Mark Weinstein, Ph.D. FDA, Center for.
Lako S, Daka A, Nurka T, Dedej T, Memishaj S
Introduction To Medical Technology
CPR 1.1. Identifying Patients and Initiating Evaluation
Patient A.
QUESTIONS ASKED IN EXAM
Human Blood Types Exist because there are three proteins that can be found on human red blood cells: A protein B protein Rh Factor [if it’s present, the.
Monthly Journal article review: Vimmi Kang PGY 2
Dr. Nishi Jaswal Assistant Professor
Introduction To Medical Technology
Regulatory Perspective of the Use of EHRs in RCTs
Presentation transcript:

Current standards, donor safety, and blood supply Workshop: Hemoglobin standards and maintaining adequate iron stores in blood donors November 8, 2011 Orieji Illoh, MD Office of Blood Research and Review Center for Biologics Evaluation and Research Food and Drug Administration

Outline Introduction. Hemoglobin standards. Workshop objectives. Regulatory history Considerations to adjusting hemoglobin standards Previous Public discussions Workshop objectives.

Introduction Consideration of the balance between donor safety and blood supply Donor safety issues. Hemoglobin standards Blood supply issues. Impact of any changes in hemoglobin standards on blood supply

Why adjust hemoglobin standards? Establish ranges within physiologic norms. Avoid donations from male donors in “anemic” range. Allow more donations from female donors in “normal” range. ~95% of hemoglobin donor deferrals occur in women. Hemoglobin deferrals have a negative impact on future blood donations.

Hemoglobin measurement Test characteristics. Simple, point of care test. Testing methods differ and are affected by physiologic and operator variables. Quantitative methods reliably measure hemoglobin within 0.2g/dL to 0.5g/dL. Relationship to donor health. Used as an indirect measurement of iron status. Studies show that hemoglobin is not a good indicator of iron stores.

Hemoglobin measurement Current requirement: 21CFR 640.3(b)(3) Blood hemoglobin level no less than 12.5g/dL or hematocrit no less than 38% in both male and female allogeneic donors. Purpose Ensure donor safety. Ensure collection of a potent product.

Chronology of FDA requirements for hemoglobin standards The threshold of 12.5g/dL was established in 1958 and has not changed. Gender specific hemoglobin standards were proposed in the past but never finalized. There have been discussions about changing hemoglobin standards in the past. 7

Considerations for Changing Hemoglobin Acceptance Standards

Definitions of anemia Group White men 20 -59 13.7 Black men 20-59 12.9 Hemoglobin levels below which 5% of the normal subjects in the population will be found (g/dL) White men 20 -59 13.7 Black men 20-59 12.9 White women 20-49 12.2 Black women 11.5 NHANES III and Scripts –Kaiser databases Blood. 2006 Mar 1;107(5):1747-50

Hemoglobin distribution in men NHANES II data: Hb concentrations in men 18 to 44 years of age. (◆) Caucasian men; (░) African American men. Transfusion. 2006 Oct;46(10):1667-81.

Hemoglobin distribution in women NHANES II data: Hb concentrations in women 18 to 44 years of age. (◆) Caucasian women; (░) African American women. Transfusion. 2006 Oct;46(10):1667-81.

Adverse effects At a minimum hemoglobin of 12.5g/dL (hct 38%) for males Underlying medical conditions may not be addressed Worsening of existing iron deficiency? At a minimum hemoglobin of 12.0g/dL (hct 36%) for females Iron deficiency?

Australian blood donors: Iron storage status of donors with different predonation thresholds Total donor population iron deficient (%) ARCBS Hb threshold from 1/1/04 Males ≥ 12.6g/dL 6.2 Females ≥ 11.8g/dL 22.0 ARCBS Hb threshold from 1/1/05 Males ≥ 13.0g/dL 6.0 Females ≥ 12.0g/dL 20.6 1535 males 1487 females Dev Biol (Basel). 2007;127:137-46.

International hemoglobin standards Single hemoglobin standard: 12.5g/dL Country Hb-male g/dL Hb-female g/dL United States 12.5 Canada Switzerland

International hemoglobin standards Gender specific: Males 13.0g/dL, Females 12.0g/dL Country Hb-male (g/dL) Hb-female France 13.0 12.0 Australia Israel

International hemoglobin standards Gender specific: Males 13.5g/dL, Females 12.5g/dL Country Hb-male g/dL Hb-female g/dL Europe: Council of Europe 13.5 12.5 United Kingdom Scotland Germany Sweden

International hemoglobin standards Gender specific: Males 13.0g/dL, Females 12.5g/dL or 11.5g/dL Country Hb-male g/dL Hb-female g/dL Brazil 13.0 12.5 Hong Kong 11.5

Effect on blood availability - Males There will be a loss of male blood donors if the hemoglobin threshold is raised. Loss of male African American donors. Special phenotype RBCs required for sickle cell patients. May impact availability of plasma from male donors.

Effect on blood availability - Females If the standard is dropped to 12.0g/dL, there may be gain of female donors.

Previous public discussions

FDA Proposed Rule (November 2007) FDA asked for comments and supporting data on: Changing the hemoglobin or hematocrit levels to 12.0g/dL or 36%, as acceptable minimal values for female allogeneic donors The possibility of adverse effects if a minimum of 12.0g/dL or hematocrit of 36% is used for females The possibility of adverse effects if a minimum of 12.5g/dL or hematocrit of 38% is maintained for males

Representative comments to the Proposed rule Wait for results of REDS II study on iron status in blood donors. Agree with proposal to lower hemoglobin standard in women to 12.0g/dL. Hemoglobin down to 12.0 g/dL is normal for females. Enormous potential to improve the blood supply. Disagree with proposal to lower hemoglobin standard in women to 12.0 g/dL. Does not have any positive benefit to the donor. May make women susceptible to iron deficiency or anemia.

Blood Products Advisory Committee: September, 2008 Topic: Iron Status in Blood Donors. Discussed alternative strategies to mitigate iron depletion. Changing Hemoglobin/hematocrit acceptance standards. Iron supplementation, dietary recommendations. Modification of interdonation interval.

Advisory Committee on Blood Safety and Availability - December 2008 Recommendations FDA should reconsider donor hemoglobin acceptance values. Adopt different, gender-appropriate acceptance values The current single value (12.5 g/dL) permits acceptance of a significant number of "anemic" males while excluding many normal females.

BPAC meeting, July 27, 2010 Committee votes Committee recommendations 10-0 to increase hemoglobin requirement for male donors. 9-0 (one abstention) against a decrease in hemoglobin requirement for female donors. Committee recommendations Await final analysis of study on blood donors before considering any changes to the interdonation interval.

Key points Donor safety issues. Blood availability issues. Blood collection from anemic males with current hemoglobin standard. Blood availability issues. Potential gain of female blood donors. Potential loss of male blood donors. http://www.anemia.org

Workshop objectives- today Obtain current information on the relationship between donor hemoglobin standards and donor safety. Discuss the effect of hemoglobin standards on blood availability. Discuss hemoglobin measurement methods in blood donors.